Radiotherapy upstaged by testicular cancer drug
This article was originally published in Clinica
The use of radiotherapy to treat the most common form of testicular cancer has received a blow with the publication today of the results of UK research into a drug application. The Medical Research Council (MRC)-funded study found that the platinum-based chemotherapy compound carboplatin outperforms, at least in the short-term, the standard form of treatment of stage I testicular cancer, radiotherapy.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.